Skip to Content


In the US, Sonidegib (sonidegib systemic) is a member of the drug class hedgehog pathway inhibitors and is used to treat Basal Cell Carcinoma.

US matches:

ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Antineoplastic agent

Chemical Name

N-{6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide (WHO)

Foreign Names

  • Sonidegibum (Latin)
  • Sonidegib (German)
  • Sonid├ęgib (French)
  • Sonidegib (Spanish)

Generic Names

  • Erismodegib (IS)
  • Erismod├ęgib (IS)
  • Erismodegibum (IS)
  • LDE 225 (IS)

Brand Names

  • Odomzo
    Novartis, United States; Novartis Pharma, Switzerland


ISInofficial Synonym
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.